Contains Nonbinding Recommendations

Draft Guidance on Mesalamine

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Mesalamine

Form/Route: Suppository/Rectal

Recommended studies: 3 studies

1. Type of study: Bioequivalence study with clinical endpoints
   Design: Parallel design, three arm (test, reference and placebo) *in-vivo*
   Strengths: 500 mg and 1000 mg
   Subjects: Patients with ulcerative proctitis
   Additional Comments: Please submit a protocol to the Clinical Review Team for recommendations on study design.

---

2. Type of study: Bioequivalence studies with pharmacokinetic endpoints (fasting)
   Design: Single-dose, two-way crossover *in-vivo*
   Strengths: 500 mg
   1000 mg, comparing to the respective strengths of the RLD
   Subjects: Normal healthy males and females, general population.
   Additional comments: Because the 500 mg and 1000 mg strengths are not proportionally similar, a bioequivalence study with clinical endpoints and a bioequivalence study with pharmacokinetic endpoints (fasting) will be needed for each strength product, if you wish to develop each strength.

Analytes to measure (Pharmacokinetic Study): Mesalamine in plasma

Bioequivalence (Pharmacokinetic Study) based on (90% CI): Mesalamine

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.